Rheos Medicines
Cambridge
About Rheos Medicines
Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease. Their approach targets the underlying cellular metabolism of immune cells to redirect the fate and function of specific cell types to treat immune-mediated disease. By simultaneously identifying new drug targets and characterizing biomarkers of disease they are bringing precision to the treatment of immune-mediated diseases. They have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $60.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2018)
- Website: rheosrx.com
- Phone: 857-777-4242
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/rheos-medicines-25716 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.